 --Data supports MYCAPSSA as non-inferior to long-acting injectable somatostatin receptor ligands iSRLs-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs-- 